Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry May

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Plos One|December 5, 2015
Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic AbnormalitiesMathilde Ghislain, Jean-Philippe Bastard, Laurence Meyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 13, 2004
Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapyXavier Duval, Valérie Journot, Catherine Leport, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 27, 2012
Is total community viral load a robust predictive marker of the efficacy of the TasP strategy?Sandrine Henard, Eliette Jeanmaire, Yohan Nguyen, et al.
AIDS (London, England)|February 16, 2007
Intermittent antiretroviral therapy in patients with controlled HIV infectionBruno Marchou, Philippe Tangre, Isabelle Charreau, et al.
Antiviral Therapy|June 27, 2007
Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial)Jean-Michel Molina, Valérie Journot, André Furco, et al.
HIV Clinical Trials|October 9, 2004
An example of nonrandom missing data for hepatitis C virus status in a prognostic study among HIV-infected patientsCharlotte Lewden, Hélène Jacqmin-Gadda, Jean-Louis Vildé, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 23, 2008
Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic)Charlotte Lewden, Thierry May, Eric Rosenthal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 10, 2009
Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 SurveyFabrice Bonnet, Christine Burty, Charlotte Lewden, et al.
Scandinavian Journal of Infectious Diseases|November 15, 2011
Relevance of fluoroquinolone use in hospitals in the Lorraine region of France before and after corrective measures: an investigation by the Antibiolor NetworkThanh Doco-Lecompte, Beatrice Demore, Sandrine Hénard, et al.
AIDS (London, England)|September 29, 2012
Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adultsChristine Durier, Corinne Desaint, Frédéric Lucht, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Plos One|December 5, 2015
Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic AbnormalitiesMathilde Ghislain, Jean-Philippe Bastard, Laurence Meyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 13, 2004
Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapyXavier Duval, Valérie Journot, Catherine Leport, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 27, 2012
Is total community viral load a robust predictive marker of the efficacy of the TasP strategy?Sandrine Henard, Eliette Jeanmaire, Yohan Nguyen, et al.
AIDS (London, England)|February 16, 2007
Intermittent antiretroviral therapy in patients with controlled HIV infectionBruno Marchou, Philippe Tangre, Isabelle Charreau, et al.
Antiviral Therapy|June 27, 2007
Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial)Jean-Michel Molina, Valérie Journot, André Furco, et al.
HIV Clinical Trials|October 9, 2004
An example of nonrandom missing data for hepatitis C virus status in a prognostic study among HIV-infected patientsCharlotte Lewden, Hélène Jacqmin-Gadda, Jean-Louis Vildé, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 23, 2008
Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic)Charlotte Lewden, Thierry May, Eric Rosenthal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 10, 2009
Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 SurveyFabrice Bonnet, Christine Burty, Charlotte Lewden, et al.
Scandinavian Journal of Infectious Diseases|November 15, 2011
Relevance of fluoroquinolone use in hospitals in the Lorraine region of France before and after corrective measures: an investigation by the Antibiolor NetworkThanh Doco-Lecompte, Beatrice Demore, Sandrine Hénard, et al.
AIDS (London, England)|September 29, 2012
Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adultsChristine Durier, Corinne Desaint, Frédéric Lucht, et al.
Pageof 6